RxDoctor Payments Data

Mark Burbridge, DO

Hematology & Oncology · North Charleston, SCNPI 1477749208

Payments from drug & device makers

$5,874in general payments, 2019–2025

Across 279 payments — averaging $21.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$947
  • Gilead$419
  • Merck$378
  • E.r. Squibb & Sons, L.L.C.$325
  • Daiichi Sankyo Inc.$298
  • Johnson & Johnson$269
  • plus $3K from 47 others

What the payments were for

  • Food & beverage$5,846100%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,874 in reported general payments places this provider in the 40th percentile of 166 hematology & oncology providers in South Carolina.

See all hematology & oncology providers in South Carolina

Medicare billing

Part B allowed, 2024
$738,658
Medicare patients
579
Services billed
22,255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide30$431,575
SprycelDasatinib30$426,788
XtandiEnzalutamide19$254,830
IbrancePalbociclib15$252,358
TagrissoOsimertinib Mesylate13$226,119
ImbruvicaIbrutinib13$212,751
PromactaEltrombopag Olamine14$211,148
NinlaroIxazomib Citrate13$160,012
EliquisApixaban115$91,661
XareltoRivaroxaban17$28,293
VeozahFezolinetant15$7,760
Dabigatran EtexilateDabigatran Etexilate Mesylate11$2,671
Hydroxyurea56$2,638
Anastrozole137$2,455
Enoxaparin Sodium15$2,096

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Sprycel$325$426,78830 claims
PfizerIbrance, Eliquis$266$344,019130 claims
Astellas Pharma US IncXtandi, Veozah$29$262,59034 claims
AstraZenecaTagrisso$232$226,11913 claims
NovartisPromacta$947$211,14814 claims
Takeda Pharmaceuticals U.S.A., Inc.Ninlaro$74$160,01213 claims
Johnson & JohnsonXarelto$269$28,29317 claims
Lilly USA, LLCOlanzapine$116$21813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 166 hematology & oncology providers in South Carolina.

Other hematology & oncology in North Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →